<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01645423</url>
  </required_header>
  <id_info>
    <org_study_id>09-VIN-105</org_study_id>
    <nct_id>NCT01645423</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Atorvastatin Calcium Tablets, 80 mg of Dr. Reddy's Under Fed Conditions</brief_title>
  <official_title>An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-way Crossover Oral BE Study of Atorvastatin Ca 80 mg Tablets of Dr. Reddy's and Lipitor 80 mg Tablets of Pfizer in Healthy Adult, Human Subjects Under Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare and evaluate the single-dose oral bioavailability and
      to monitor the safety of subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open label, balanced, randomized, two-treatment, two-period, two-way crossover oral
      bioequivalence' study of Atorvastatin Calcium 80 mg Tablets of Dr. Reddy's and Lipitor 80 mg
      Tablets of Pfizer Ireland Pharmaceuticals in healthy adult, human subjects under fed
      conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under curve (AUC)</measure>
    <time_frame>Pre-dose at 0.00 hour and post-dose at 0.25, 0.50, 0.75, 1.00, 1.25, 1.50 1.75, 2.00, 2.25,2.50, 2.75, 3.00, 3.33, 3.67,4.00,4.50, 5.00,6.00, 8.00, 10.00, 12.00, 16.00,24.00, 36.00, 48.00 and 72.00 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Atorvastatin Calcium Tablets, 80 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atorvastatin Calcium Tablets, 80 mg of Dr. Reddy's Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lipitor 80 mg Tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lipitor 80 mg Tablets of Pfizer Ireland Pharmaceuticals</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin Calcium Tablets, 80 mg</intervention_name>
    <description>Atorvastatin Calcium Tablets, 80 of Dr. Reddy's Laboratories Limited</description>
    <arm_group_label>Atorvastatin Calcium Tablets, 80 mg</arm_group_label>
    <arm_group_label>Lipitor 80 mg Tablets</arm_group_label>
    <other_name>Lipitor 80 mg Tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects aged between 18 and 45 years (both inclusive).

          2. Subjects' weight within normal range according to normal values for Body Mass Index (1
             8.5 to 24.9 kg/m2) with minimum of 50 kg weight.

          3. Subjects with normal health as determined by personal medical history, clinical
             examination and laboratory examinations (Annexure IIIa) within the clinically
             acceptable reference range (Annexure IIIb).

          4. Subjects having normal 12-lead electrocardiogram (ECG).

          5. Subjects having normal chest X-Ray (P/A view) whose X-Ray was taken not more than 6
             months prior to the dosing of Period 0 1.

          6. Subjects having negative urine screen for drugs of abuse (including amphetamines,
             barbiturates, benzodiazepines, marijuana, cocaine, and morphine).

          7. Subjects having negative alcohol breath test.

          8. Subjects willing to adhere to the protocol requirements and to provide written
             informed consent.

        Exclusion Criteria:

        Subjects will be excluded from the study, if they meet any of the following criteria:

          1. Hypersensitivity to Atorvastatin or related class of drugs.

          2. History or presence of significant cardiovascular, pulmonary, hepatic, renal,
             gastrointestinal, endocrine, immunological, dermatological, neurological or
             psychiatric disease or disorder.

          3. Any treatment which could bring about induction or inhibition of hepatic microsomal
             enzyme system within 1 month of the study starting.

          4. History or presence of significant alcoholism or drug abuse in the past one year.

          5. History or presence of significant smoking (more than 10 cigarettes or beedi's/day).

          6. History or presence of asthma, urticaria or other significant allergic reactions.

          7. History or presence of significant gastric andlor duodenal ulceration.

          8. History or presence of significant thyroid disease, adrenal dysfunction, organic
             intracranial lesion such as pituitary tumor.

          9. History or presence of cancer.

         10. Difficulty with donating blood.

         11. Difficulty in swallowing solids like tablets or capsules.

         12. Use of any prescribed or OTC medication during last two weeks prior to dosing in
             period 0 1.

         13. Major illness during 3 months before screening.

         14. Participation in a drug research study within past 3 months.

         15. Donation of blood in the past 3 months before screening.

         16. Consumption of grapefruit juice, xanthine-containing products, tobacco containing
             products or alcohol for within 48 hours prior to dosing.

         17. Positive screening test for any one or more: HIV, Hepatitis B and Hepatitis C.

         18. History or presence of significant easy bruising or bleeding.

         19. History or presence of significant recent trauma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Dharmesh Domadia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Veeda Clinical Research Pvt. Ltd.,</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Veeda Clinical Research Pvt. Ltd.,</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujrat</state>
        <zip>3 80015,</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2012</study_first_submitted>
  <study_first_submitted_qc>July 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2012</study_first_posted>
  <last_update_submitted>July 19, 2012</last_update_submitted>
  <last_update_submitted_qc>July 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Atorvastatin calcium</keyword>
  <keyword>crossover</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

